Pre-made Navicixizumab benchmark antibody ( Bispecific mAb, anti-DLL4;VEGFA therapeutic antibody, Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Navicixizumab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Navicixizumab is an anti-DLL4/VEGF bispecific antibody that has demonstrated robust in vivo antitumor efficacy in a number of solid tumor xenografts. In the phase Ia trial of the monotherapy, 66 patients with various solid tumors were treated once every 3 weeks in 1 of 8 dose-escalation cohorts or an expansion cohort.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-369-1mg	1mg	Inquiry
GMP-Bios-ab-369-10mg	10mg	Inquiry
GMP-Bios-ab-369-100mg	100mg	Inquiry
GMP-Bios-ab-369-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Navicixizumab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibody
INN Name	Navicixizumab
Target	DLL4;VEGFA
Format	Bispecific mAb
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa;Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2015
Year Recommended	2016
Companies	OncoMed Pharmaceuticals
Conditions Approved	na
Conditions Active	Fallopian tube cancer;Ovarian cancer;Peritoneal cancer
Conditions Discontinued	Colorectal cancer;Solid tumours
Development Tech	na